Shubham Kumar

Mr. Shubham Kumar


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in ChemistryOpen
Verified
Journal Article
Open access
SGSneha Gupta
Sneha Gupta
SJSumeet Jha
Sumeet Jha
SRSupriya Rani
Supriya Rani
PAPinky Arora
Pinky Arora
SKShubham Kumar
Shubham Kumar
2,4‐Thiazolidinedione derivatives represent nitrogen‐containing heterocyclic compounds utilized in type 2 diabetes mellitus management. Recent advances in medicinal chemistry have unveiled diverse therapeutic potentials and structural modifications of these derivatives. This review delves into novel TZD derivatives, encompassing their synthesis, structure‐activity relationships, and pharmacokinetic profiles. Various therapeutic potentials of TZDs are explored, including anticancer, antimicrobial, anti‐inflammatory, antioxidant, anticonvulsant, antihyperlipidemic, anticorrosive, and antitubercular activities. Additionally, it addresses mitigating side effects associated with marketed TZD derivatives such as weight gain, oedema, fractures, and congestive heart failure in type 2 diabetes mellitus management. The review elaborates on in vivo, in vitro, and ex vivo studies supporting different biological activities, alongside predicting ADME and drug‐likeness properties of TZDs. Computational studies are also integrated to elucidate binding modes and affinities of novel TZD derivatives. Furthermore, a plethora of novel TZD derivatives with varied and enhanced therapeutic potentials are presented, warranting further evaluation of their biological activities.

24 March 2025 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
PAPinky Arora
Pinky Arora
SWSwati
Swati
SRSupriya Rani
Supriya Rani
SJSumeet Jha
Sumeet Jha
SGSneha Gupta
Sneha Gupta
SKShubham Kumar
Shubham Kumar


14 March 2024 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
JSJagtar Singh
Jagtar Singh
MSMohit Sharma
Mohit Sharma
HSHarmeet Singh
Harmeet Singh
PAPinky Arora
Pinky Arora
PUPuneet Utreja
Puneet Utreja
SKShubham Kumar
Shubham Kumar

1 October 2024 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
SKShubham Kumar
Shubham Kumar
PAPinky Arora
Pinky Arora
PWPankaj Wadhwa
Pankaj Wadhwa
PKParanjeet Kaur
Paranjeet Kaur
Background: Prostate cancer is one of the most prevalent cancers in men, leading to the second most common cause of death in men. Despite the availability of multiple treatments, the prevalence of prostate cancer remains high. Steroidal antagonists are associated with poor bioavailability and side effects, while non-steroidal antagonists show serious side effects, such as gynecomastia. Therefore, there is a need for a potential candidate for the treatment of prostate cancer with better bioavailability, good therapeutic effects, and minimal side effects.Objective: This current research work focused on identifying a novel non-steroidal androgen receptor antagonist through computational tools, such as docking and in silico ADMET analysis.Methods: Molecules were designed based on a literature survey, followed by molecular docking of all designed compounds and ADMET analysis of the hit compounds.Results: A library of 600 non-steroidal derivatives (cis and trans) was designed, and molecular docking was performed in the active site of the androgen receptor (PDBID: 1Z95) using Auto- Dock Vina 1.5.6. Docking studies resulted in 15 potent hits, which were then subjected to ADME analysis using SwissADME. ADME analysis predicted three compounds (SK-79, SK-109, and SK-169) with the best ADME profile and better bioavailability. Toxicity studies using Protox-II were performed on the three best compounds (SK-79, SK-109, and SK-169), which predicted ideal toxicity for these lead compounds.Conclusion: This research work will provide ample opportunities to explore medicinal and computational research areas. It will facilitate the development of novel androgen receptor antagonists in future experimental studies.

27 June 2025 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
PAPinky Arora
Pinky Arora
ARAditi Rana
Aditi Rana
AKAzmat Ali Khan
Azmat Ali Khan
AAAmer M. Alanazi
Amer M. Alanazi
PWPankaj Wadhwa
Pankaj Wadhwa
RKRubal Kalra
Rubal Kalra